ANTHOS THERAPEUTICS
Accelerating the development of life-preserving therapies for patients at high-risk of cardiovascular diseases

About Anthos

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.

Anthos is a formation of Blackstone (NYSE: BX) Life Sciences and Novartis AG (NYSE: NVS), one of the worlds’ leading pharmaceutical companies. The company is led by a world-class executive team highly experienced in the successful development of therapies for cardiovascular disease.

About MAA868

Anthos’s lead program is MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. Early clinical trials indicate MAA868 has the potential to prevent a variety of cardiovascular disorders with minimal or no bleeding risk within a new, long acting treatment paradigm, thus providing major advantages over the conventional standards of care.

MAA868 Icon

High-risk patients

Thrombotic disorders are estimated to account for one in four deaths and are the leading cause of mortality worldwide. Thrombotic disorders can affect arteries or veins, manifesting as ischemic stroke, peripheral artery disease, venous thromboembolism, and many debilitating orphan diseases.

MAA868 Icon

High unmet need

A large unmet medical need exists for next generation anti-thrombotic therapies in patients currently underserved by conventional anticoagulant therapies. Many patients with, or at risk of, thrombotic disorders continue to experience blood clots or have life-threatening bleeds on anticoagulant medications. Many patients are not prescribed anticoagulants at all because of the risk of bleeding.

MAA868 Icon

Targeted therapy

MAA868 is a novel, fully human, potent Factor XI antibody that uniquely binds with high affinity both active enzyme and zymogen. Single subcutaneous doses of MAA868 in a clinical study exhibited strong long-lasting anticoagulant activity in humans and a promising safety profile. MAA868 effectively reduces Factor XI for more than 4 weeks, representing a potential once-monthly subcutaneous anti-thrombotic agent.

Management Team

Alex Yi


Alex Yi Photo

Dan Bloomfield


Dan Bloomfield Photo

Debra Freedholm


Debra Freedholm Photo

Janeen Salter


Janeen Salter Photo

Jessica Patrick Seabrook


Jessica Patrick Seabrook Photo

John Glasspool


John Glasspool Photo

Jonathan Freeman, Ph.D.


Jonathan Freeman Photo

Lynn Mallett


Lynn Mallett Photo

Nik Mehta


Nik Mehta Photo

Yasser Khder


Yasser Khder Photo

Board of Directors

Nicholas Galakatos, Ph.D.


Nick Galakatos Photo

Paris Panayiotopoulos


Paris Panayiotopoulos Photo

Scott Beardsley


Scott Beardsley Photo

Ari Brettman, M.D.


Ari Brettman Photo

Shaun Coughlin, M.D., Ph.D.


Shaun Coughlin Photo

Richard Pasternak, M.D.


Richard Pasternak Photo

Greg Norden


Greg Norden Photo

Our Investors

Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life-cycle of companies and products within the key life science sectors. Investments are of sufficient scale to allow companies or products to reach meaningful value inflection points and are made in conjunction with hands-on operational leadership. In launching this new platform, Blackstone acquired Clarus, a leading global life-sciences firm.

News

Press

Anthos Therapeutics dubbed one of the fiercest biotech companies in the world.

Read More

Blackstone Life Sciences and Novartis Create Anthos Therapeutics to Develop Innovative Targeted Medicines for Cardiovascular Disease

Read More

Publications

Koch AW, Schiering N, Melkko S, et al. MAA868—a novel FXI antibody with a unique binding mode—shows durable effects on markers of anticoagulation in humans. Blood 2019; blood-2018-10-880849.

https://doi.org/10.1182/blood-2018-10-880849

Accessed February 21, 2019